Virtual Library

Start Your Search

Xiaoling Chen



Author of

  • +

    P09 - Health Services Research/Health Economics - Real World Outcomes (ID 121)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Health Services Research/Health Economics
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P09.29 - Immune-Related Adverse Events and their Association with Effectiveness of PD-1/PD-L1 Inhibitors in NSCLC: A Real-World Study from China (ID 2086)

      00:00 - 00:00  |  Presenting Author(s): Xiaoling Chen

      • Abstract
      • Slides

      Introduction

      Programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors are increasingly used in China, but no real-world data are available about the immune-related adverse events (irAEs). This real-world retrospective study aimed to assess the safety and effectiveness of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer (NSCLC) and to analyze the association between irAEs and effectiveness.

      Methods

      This was a retrospective study of the clinical information of patients with non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors from August 2016 to November 2019 at the Thoracic Medicine of Beijing Cancer Hospital.The patients were divided into irAE or non-irAE groups. Overall adverse events, impact of irAE on tumor response, and association of irAEs with effectiveness were evaluated.

      Results

      One hundred and ninety-one patients were included in this study, including 70 (36.6%) patients in IrAE Group and 121 (63.4%) patients in Non-irAE Group. AE, grade 3-5 AEs, and IrAE were occurred in 107 (56.0%), 24 (12.6%) and 70 (36.6%) of 191 patients respectively. The objective response rate (ORR) and disease control rate (DCR) were higher in irAE Group compared with Non-irAE Group (42.0% vs. 25.8%, P=0.038; 91.9% vs. 70.8%, P=0.002). Multivariable analyses identified irAE associated with progression-free survival (HR=0.62, 95%CI: 0.43-0.91; P=0.015), but not with overall survival (HR=0.76, 95%CI: 0.44-1.28; P=0.299).

      Conclusion

      In NSCLC treated with PD-1/PD-L1 inhibitors, patients with irAEs showed improved effectiveness over patients without irAEs. Future studies of anti-PD-1/PD-L1 immunotherapy should address this association to explore the underlying biological mechanisms of efficacy.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.